BioInvent International AB (publ) (STO:BINV)

Market Cap	2.50B
Revenue (ttm)	60.80M
Net Income (ttm)	-468.06M
Shares Out	65.80M
EPS (ttm)	-7.12
PE Ratio	n/a
Forward PE	3.90
Dividend	n/a
Ex-Dividend Date	n/a

Volume	32,385
Average Volume	60,068
Open	38.85
Previous Close	38.90
Day's Range	37.65 - 38.85
52-Week Range	22.70 - 50.80
Beta	-0.05
RSI	51.55
Earnings Date	Aug 26, 2025

About Splunk

BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company’s drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and a type of blood cancer; BI-1206, an anti-FcyRIIB antibody in Phase 1/2a trial for the treatment of non-Hodgkin’s lymphoma, as well as Phase 1/2a trial to treat advanced solid tumors; BI-19...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 114
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: BINV

Financial Performance

In 2024, STO:BINV's revenue was 44.69 million, a decrease of -37.47% compared to the previous year's 71.46 million. Losses were -429.38 million, 30.0% more than in 2023.